German Validation Study of the Subjective Cognitive Decline Questionnaire (SCD-Q)

Launched by LUDWIG-MAXIMILIANS - UNIVERSITY OF MUNICH · Nov 27, 2024

Keywords

ClinConnect Summary

The German Validation Study of the Subjective Cognitive Decline Questionnaire (SCD-Q) is a clinical trial aimed at improving our understanding of how people perceive their own memory and thinking abilities, particularly in the context of Alzheimer’s disease. The SCD-Q is a tool that helps measure self-reported changes in cognitive function, but it hasn't been specifically tested for German speakers yet. This study is important because validating the questionnaire in German will help doctors better assess and support patients experiencing memory issues.

To participate in this study, individuals need to have an upcoming medical appointment for dementia evaluation at the Alzheimer Therapy and Research Center in Germany. They also must be able to provide written consent and understand the study. However, people with very advanced dementia or those who cannot read or write will not be eligible. Participants can expect to complete the SCD-Q questionnaire, which could help improve future care for those experiencing cognitive decline. Overall, this study will contribute to better tools for diagnosing and understanding Alzheimer’s disease in German-speaking populations.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Medical appointment for dementia diagnostics at the Alzheimer Therapie- und Forschungszentrum
• • Provision of signed, written and dated informed consent
• • Capacity to give informed consent
• Exclusion Criteria:
• • dementia in a very advance stage
• • Illiteracy